2002
DOI: 10.1016/s0140-6736(02)07679-1
|View full text |Cite
|
Sign up to set email alerts
|

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

6
303
0
6

Year Published

2004
2004
2019
2019

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 429 publications
(315 citation statements)
references
References 13 publications
6
303
0
6
Order By: Relevance
“…This was perhaps best observed with STI-571 (Gleevec, imatinib mesylate, Novartis Pharma, Basel, Switzerland), a competitive inhibitor of the ATP-binding site of many kinases (Klejman et al, 2002). The wide clinical application of STI-571 is partially due to its ability to inhibit many kinases, including bcrabl, platelet-derived growth factor receptors, and c-Kit (Heinrich et al, 2000;McGary et al, 2002;von Bubnoff et al, 2002). The relatively nonspecific activity of STI-571 results in activity against Kit and the PDGFR in gastrointestinal stromal tumours (GIST) and against the PDGFR in hypereosinophilic syndrome.…”
Section: Discussionmentioning
confidence: 99%
“…This was perhaps best observed with STI-571 (Gleevec, imatinib mesylate, Novartis Pharma, Basel, Switzerland), a competitive inhibitor of the ATP-binding site of many kinases (Klejman et al, 2002). The wide clinical application of STI-571 is partially due to its ability to inhibit many kinases, including bcrabl, platelet-derived growth factor receptors, and c-Kit (Heinrich et al, 2000;McGary et al, 2002;von Bubnoff et al, 2002). The relatively nonspecific activity of STI-571 results in activity against Kit and the PDGFR in gastrointestinal stromal tumours (GIST) and against the PDGFR in hypereosinophilic syndrome.…”
Section: Discussionmentioning
confidence: 99%
“…The majority of patients with Ph þ ALL who relapse during the treatment with a TKI carry bcr-abl TKD mutations that display high IC 50 values in biochemical and cellular assays, 13,20,21 implying that they have a causal role in acquired imatinib resistance. 12 --19 Their role in primary resistance commonly observed in Ph þ ALL recurring after chemotherapy is uncertain, and it also remains to be determined when these mutations first develop.…”
Section: Discussionmentioning
confidence: 99%
“…Retrospective analysis of pretreatment specimens using allele-specific oligonucleotide PCR (ASO-PCR) was able to demonstrate low levels of mutant cDNA in all four cases, indicating clonal selection. Similarly, von Bubnoff et al (2002) noted an increase in the proportion of mutant mRNA with sequential monitoring of relapsing patients.…”
Section: When Do Resistant Mutations Arise?mentioning
confidence: 90%
“…Despite good haematological response, in most cases relapse occurred early with a median survival of only 20 -30 weeks. Relapse is commonly associated with emergence of mutations in the BCR-ABL kinase (Gorre et al, 2001;von Bubnoff et al, 2002).…”
Section: Imatinib In Blast Crisis and Ph þ Acute Lymphoblastic Leukaementioning
confidence: 99%